| Biomarker ID | 664 |
| PMID | 21626193 |
| Year | 2011 |
| Biomarker | Dihyroxybutanoic acid + Pyrimidine + Xylonic acid + Xylopyranose + Ribofuranoside |
| Biomarker Basis | Expression Based |
| Biomolecule | Metabolites |
| Source | Urine |
| Subjects | Humans |
| Regulation | Upregulated in PCA: (Dihyroxybutanoic acid, Xylonic acid); Downregulated in PCA: (Pyrimidine, Xylopyranose, Ribofuranoside) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | PCa Vs Non Cancerous (healthy+BPH) |
| Type of Biomarker | Diagnostic |
| Cohort | 20 patients with Prostate Cancer alog woth 8 patients wth BPH and 20 healthy controls were used for this study. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.825 |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Isotope dilution gas chromatography/ mass spectrometry (ID GC/MS) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |